P160048/S031: Eversense Continuous Glucose Monitoring System
FDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS) protocol.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Senseonics, Incorporated. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Mar 19, 2026 to Mar 19, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QCD appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P160048, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 20451 Seneca Meadows Pkwy., Germantown, MD, 20876. Recorded on P160048/S031, decision dated Mar 19, 2026.
Continuous glucose monitor, implanted, adjunctive use.
FDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS) protocol.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Eversense Continuous Glucose Monitoring SystemP160048/S031 | Senseonics, Incorporated | PMA supplement | Mar 19, 2026 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.